I. The Industry Alarm Behind 1.3TB
In June 2026, a well-known Danish pharmaceutical giant disclosed a cybersecurity incident. A ransomware group claimed that they had infiltrated the company’s internal network for more than two months, stealing approximately 1.3TB of data. After being refused a $25 million ransom, they were planning to split and sell the data. The stolen data covered enterprise source code, exclusive R&D materials for both marketed and unmarketed drugs, clinical trial data, employee and patient personal information, and internal data from the company’s self-developed AI models. The company subsequently confirmed that the incident affected the data of some clinical trial participants, with potentially exposed information including randomly assigned patient identification codes, participation details, gender, year of birth, biomarker information, and health or immunological data.
This is not an isolated case. In the same year, another biotechnology company reported a cyber incident involving the theft of patient information and proprietary data stored on cloud servers. And as early as 2025, a major Indian electronics and semiconductor manufacturing company also suffered a ransomware attack, with more than 630GB of component design files leaked. Core data in the pharmaceutical manufacturing industry is becoming a key target for both attackers and internal leakers.
Data protection in the pharmaceutical manufacturing industry faces threefold叠加 pressure. The first is the extremely high value of the data itself. The R&D investment for an innovative drug is measured in billions. Clinical trial data, process formulas, GMP production parameters, and biomarker information constitute the enterprise’s most core competitive barrier. A single leak of clinical data could allow years of R&D investment to be “reverse-engineered” by competitors into a shortcut. The second is the rigid constraint of regulation. In February 2026, five ministries jointly issued the “Measures for the Management of Data Security and Personal Information Protection in Medical and Health Institutions (Trial),” explicitly requiring that processing logs involving core data be retained for no less than three years, and that personnel outside the institution must not perform remote O&M under unregulated conditions. In June of the same year, fourteen departments listed “strictly safeguarding medical data security” as an independent task, strictly prohibiting leakage, trafficking, and unauthorized use. The third is the high complexity of data flow scenarios. Data in pharmaceutical enterprises needs to flow frequently among R&D departments, clinical research institutions, CRO companies, CDMO partners, and regulatory agencies. Each flow involves multiple compliance requirements such as cross-border data compliance, informed consent authorization, and de-identification processing.
II. Three “Special Characteristics” of Pharmaceutical Data Leak Prevention
Unlike industries such as IT and Internet and finance, data leak prevention in the pharmaceutical manufacturing industry has its own unique structural challenges.
- First, the “dual attribute” of the protected object. A piece of clinical trial data is both the enterprise’s trade secret and the trial subject’s personal information. It needs to be prevented from being obtained by competitors, while also ensuring that it can be reviewed by regulatory agencies, used by research institutions, and processed by partners in compliant scenarios. “It cannot be unmanaged, nor can it be managed to death” —this is the fundamental contradiction of pharmaceutical data leak prevention. Traditional DLP solutions often adopt a “one-size-fits-all” blocking strategy, which in the pharmaceutical industry directly hinders the efficiency of new drug R&D and clinical collaboration.
- Second, the “multi-line parallel” of compliance requirements. Pharmaceutical enterprises need to simultaneously satisfy GMP data integrity requirements, GCP clinical trial standards, the Data Security Law, the Personal Information Protection Law, and industry regulatory requirements. GMP requires electronic records to have complete audit trails that can reproduce the generation, modification, and deletion processes of user management and system settings. GCP requires clinical trial data to be encrypted and de-identified during transmission and processing, and to follow the principle of informed consent. These compliance requirements are scattered across different regulatory systems. If they are addressed separately by multiple security systems, management complexity will rise exponentially.
- Third, the “cross-boundary nature” of flow paths. Data flow in pharmaceutical enterprises occurs not only within the enterprise but also extensively involves external collaboration. CRO companies need to receive clinical trial data from sponsors, CDMOs need to obtain process parameters, and central laboratories need to return raw data in real time. In these flows, data may be transmitted through multiple channels such as email, instant messaging, cloud drives, and API interfaces, and each channel is a potential risk exposure point.
III. From “Multi-Point Blocking” to “Integrated Governance”: Ping64’s Solution Logic
The traditional approach to pharmaceutical data leak prevention is to deploy security tools separately at each risk point: one set for endpoint encryption, one set for DLP, one set for auditing, and another set for cross-network exchange. The result is that the security team needs to maintain multiple systems simultaneously, policy configurations conflict with one another, audit data is stored in a scattered manner, and every compliance audit requires manually piecing together evidence chains from multiple systems.
The core breakthrough of the Ping64 integrated office security platform is: it does not treat data security as a stack of independent functions, but enables all security capabilities to operate collaboratively on the same data foundation and policy engine. For the pharmaceutical manufacturing industry, this means shifting from “multi-point blocking” to “integrated governance”—the anchor of control is not a certain channel or a certain system, but the security attributes carried by the data itself.
IV. Making Every Piece of Data “Protected from Birth”
The starting point of pharmaceutical data leak prevention is not outbound control, but data creation. Ping64’s approach is to determine protection attributes at the moment of file creation. When a document is created or saved in a controlled application, the content identification engine automatically determines its sensitivity level and triggers corresponding protection actions. The platform deploys a multi-dimensional intelligent identification engine capable of automatically discovering and classifying sensitive information such as patient privacy data, electronic medical records, and GCP clinical trial data.
The core value of this capability is: researchers do not need to know “whether this clinical data is sensitive”—the system already knows in advance. When a researcher saves a document containing a core formula on an office computer, the system automatically identifies its sensitivity level and triggers encryption protection, eliminating the risk of data exposure from the source.
On the endpoint side, transparent document encryption sinks encryption and decryption logic down to the operating system kernel layer. When authorized processes read or write specified file types, encryption and decryption are completed automatically, while unauthorized processes always receive ciphertext. This means that even if a clinical trial data file is copied to an unauthorized location, synchronized to a personal cloud drive, or transmitted through an uncontrolled channel, the file content remains under encryption protection. Ping64 supports deep compatibility with mainstream pharmaceutical R&D tools and office software and will not cause R&D work lag or file corruption due to encryption.
V. Channel Control: Making Compliant Flow “Workable” and Non-Compliant Outbound Transfer “Impossible”
The complexity of pharmaceutical data leak prevention lies in the fact that enterprises need to strictly control data outbound transfers while also ensuring smooth data flow in compliant scenarios. Submitting application materials to regulatory agencies, providing clinical trial data to CRO companies, and transmitting process parameters to CDMOs—these outbound behaviors are completely necessary in business terms. If they are blocked in a “one-size-fits-all” manner, it will seriously affect R&D progress and compliance applications.
Ping64 covers all common outbound channels in pharmaceutical enterprises: email, instant messaging, cloud drive synchronization, browser uploads, USB copying, and printing. The system can parse file content in real time. Once sensitive information is identified, it automatically triggers prompts, approval, blocking, encryption, or watermarking according to policies. Ping64 DLP deeply integrates with cloud desktop environments, with content identification, classification and grading, behavior auditing, and outbound control as its core, achieving integrated protection of “data does not leave the cloud, plaintext does not leave the endpoint, and risks are traceable.”
The key lies in the “context awareness” of the approval process. When a researcher initiates a file outbound request, the approval interface displays not only the file name and application reason, but also the file content summary, sensitivity level, applicant’s endpoint compliance status, historical outbound records, recipient identity, and historical cooperation records. Approvers can make judgments based on complete information, rather than guessing “whether this file can be sent” based solely on a file name. After approval, the system automatically processes the outbound file: adding tracing watermarks, setting validity periods, limiting the number of openings, and embedding tracing identifiers. For sensitive scenarios such as cross-border transfer of clinical trial data, the system can configure mandatory approval policies to ensure that every cross-border data flow undergoes compliance review and informed consent verification.
VI. Endpoint Security Hardening in GMP Scenarios
The endpoint environment in the pharmaceutical manufacturing industry has its particularities. GMP-related computerized systems require electronic records to have complete audit trails that can reproduce the generation, modification, and deletion processes of user management and system settings. IT management PCs connected to laboratory instruments need to comply with 21 CFR Part 11, EU Annex 11, and ALCOA+ data integrity principles.
Ping64’s design logic in pharmaceutical endpoint scenarios is “embedding control into the workflow”—allowing authorized users to continue working normally and making it impossible for unauthorized actions to happen quietly. The system supports whitelist control of applications on GMP-related endpoints, allowing only validated software to run; conducts full-process auditing of critical operations, recording file creation, modification, deletion, and export behaviors; and performs approval and tracing of data export behaviors, ensuring that every piece of GMP data leaving the controlled environment has a complete flow record.
For laboratory endpoints in pharmaceutical enterprises, Ping64 can identify and control data export behavior, preventing researchers from taking experimental data out of the controlled environment through USB drives or unauthorized software. For industrial control endpoints in production workshops, Ping64 adopts a “stability-first” control strategy, restricting peripheral port usage, prohibiting the installation of new software, and distributing patches according to production rhythm, ensuring that production line operation is not affected.
VII. Leak Tracing: From “Having Logs” to “Having Evidence”
Investigations of pharmaceutical data leak incidents often face a common dilemma: the enterprise can confirm that “data was leaked,” but cannot answer “who took the data out, at what time, and through what method.” Without a continuous, reviewable evidence chain, accountability and compliance reporting are difficult to implement.
Ping64’s leak tracing capability restores outbound behavior into traceable, filterable, and reviewable audit events. The system automatically, in real time, and around the clock records every step of file actions on endpoint computers—local creation, modification, deletion, renaming, as well as operational behaviors such as USB copying, cloud drive uploads, instant messaging outbound transfers, email outbound transfers, and printing—forming solid underlying data. After integrating sensitive content identification, the system automatically filters out sensitive incidents involving core secrets from massive logs, labels flow logs as “sensitive” and highlights warnings, so auditors do not need to review ordinary files one by one.
When a security officer discovers that a sensitive file has been abnormally sent out, they only need to select that record and click “Trace Flow Trajectory.” The system will then use that file as the core node to automatically generate a visualized panoramic map of file flow, presenting the complete chain from creation, modification, and renaming to multi-channel outbound transfer. This leap from “having logs” to “having evidence” is of particular significance for compliance audits and regulatory inspections in the pharmaceutical industry. When regulatory agencies require GMP data integrity evidence, enterprises need to provide not just an operation log, but a complete evidence chain—who created the data, whose edits and transfers it went through, at what point it was exported, through which channel, and whether approval was obtained. The answers to these questions together constitute a complete compliance basis.
VIII. Governance Value of the Integrated Platform for the Pharmaceutical Industry
Integrating content identification, endpoint encryption, channel control, approval processes, and tracing identifiers on the same platform provides governance value in the pharmaceutical industry through three “eliminations.”
- Eliminating compliance blind spots. Pharmaceutical enterprises need to simultaneously satisfy GMP, GCP, the Data Security Law, the Personal Information Protection Law, and industry regulatory requirements. In a multi-system architecture, each system can only cover a fragment of compliance requirements, and the security team needs to spend a great deal of time piecing together evidence and verifying policies. Ping64’s unified audit center stores endpoint behavior audits, file outbound records, and approval process logs in association, forming a complete, coherent, and tamper-proof evidence chain. Administrators can enter a file fingerprint or user account to simultaneously retrieve all relevant records for that file or person, without switching between multiple systems.
- Eliminating collaboration barriers. Pharmaceutical R&D is highly dependent on external collaboration. Partners such as CROs, CDMOs, and central laboratories need to receive and process data within a compliant framework. Ping64 supports controlled outbound formats: files are transmitted in encrypted form, and the recipient needs to open them in a specified environment. Upon opening, it automatically connects to the verification server for identity verification and permission checks. Files cannot be forwarded, copied, or saved as other formats, ensuring the secure flow of core R&D data in the supply chain. This mechanism both satisfies collaboration needs and ensures controllability of data in external environments.
- Eliminating response delays. When the DLP module identifies that sensitive data is being sent out, the system can automatically trigger the file transfer control module to block the current operation, simultaneously start screen recording to capture the on-site scene, and notify administrators for manual review. When the endpoint security status changes, transfer permissions are automatically adjusted. This cross-module automated linkage compresses the time window from “discovering risk” to “controlling risk” to near-synchronous levels.
IX. From “Post-Mortem Regret” to “Full-Process Traceability”
Core data protection in the pharmaceutical manufacturing industry cannot rely on employee self-discipline, nor can it rely on post-event accountability. The R&D cycle of an innovative drug is measured in years, and a single data leak can make years of investment go down the drain. Truly effective protection is to keep core data protected from the moment it is created, and this protection does not depend on the user’s security awareness or affect R&D efficiency.
What the Ping64 integrated office security platform provides for the pharmaceutical manufacturing industry is precisely such a protection mechanism: content identification to determine data sensitivity levels, endpoint encryption to give data protection attributes, channel control to restrict outbound paths, approval processes to verify outbound compliance, and tracing identifiers to maintain controllability after outbound transfer. These capabilities operate collaboratively on the same platform, enabling pharmaceutical enterprises to establish a complete leak prevention closed loop from endpoint to outbound, from usage to auditing, without sacrificing R&D efficiency.
In an era where innovative drug R&D is increasingly globalized, medical data regulation continues to escalate, and supply chain collaboration is increasingly complex, making every piece of core data leave the enterprise environment with “safe factory” attributes may be the most pragmatic protection for the core competitiveness of the pharmaceutical manufacturing industry.
Contact
16 min 
